NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies (UFPT), today announced Jeffrey Bailly, Chairman and CEO and Ron Lataille, Sr. Vice President & CFO, will present at the East Coast IDEAS Investor Conference on Wednesday, June 11, 2025 at The Westin Times Square in New York, NY. UFP’s presentation is scheduled to begin at 7:55 AM ET. The presentation is webcast and can be accessed through the conference host’s main website: https://www.threepartadvisors.com/east-coast and in the investo ...

NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Jeffrey Bailly, Chairman and CEO, and Ron Lataille, Sr. Vice President & CFO, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025. UFP’s fireside chat is scheduled to begin at 11:20 AM ET. About UFP Technologies, Inc. UFP Technologies is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other h ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR (Mark one) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2025 Commission File Number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or oth ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In April, I called UFP Technologies (NASDAQ: UFPT ) a medical sterile producer which looked quite clean in a premium article in my service. Following a 50% stock pullback, the custom medical compo ...

Financial Performance - Net income for Q1 2025 was $17.2 million, a 35.4% increase from $12.7 million in Q1 2024, with diluted earnings per share rising to $2.21 from $1.64[2][10] - Net sales for Q1 2025 reached $148.1 million, up 41.1% from $105.0 million in Q1 2024, with medical market sales increasing by 50.4% to $135.4 million[4][10] - Operating income for Q1 2025 increased by 45.2% to $23.1 million, compared to $15.9 million in Q1 2024, with adjusted operating income rising 49.5% to $25.8 million[4][10] - Adjusted EBITDA for Q1 2025 increased by 45.9% to $30.2 million from $20.7 million in Q1 2024[10] - Operating income (GAAP) for Q1 2025 was $23,126 thousand, up from $15,924 thousand in Q1 2024, representing a 45.5% increase[20] - Adjusted operating income (Non-GAAP) increased to $25,813 thousand in Q1 2025 from $17,270 thousand in Q1 2024, a growth of 49.5%[20] - Net income (GAAP) rose to $17,184 thousand in Q1 2025, compared to $12,693 thousand in Q1 2024, reflecting a 35.2% increase[24] - Adjusted net income (Non-GAAP) for Q1 2025 was $19,206 thousand, up from $13,706 thousand in Q1 2024, marking a 40.0% increase[24] - Adjusted net income per diluted share outstanding (Non-GAAP) increased to $2.47 in Q1 2025 from $1.77 in Q1 2024, a rise of 39.3%[24] - EBITDA (Non-GAAP) for Q1 2025 was $27,724 thousand, compared to $18,964 thousand in Q1 2024, indicating a 46.2% increase[27] - Adjusted EBITDA (Non-GAAP) reached $30,236 thousand in Q1 2025, up from $20,724 thousand in Q1 2024, representing a 45.8% growth[27] Expenses and Efficiency - Selling, general, and administrative expenses (SG&A) rose 34.6% to $18.7 million, but as a percentage of sales, SG&A decreased to 12.6% from 13.2%[4] - SG&A (GAAP) expenses increased to $18,725 thousand in Q1 2025 from $13,912 thousand in Q1 2024, a rise of 34.5%[22] - Adjusted SG&A (Non-GAAP) as a percentage of sales decreased to 11.0% in Q1 2025 from 12.2% in Q1 2024, showing improved efficiency[22] Business Developments - The company has secured exclusive manufacturing rights for a significant portion of its Safe Patient Handling business through June 2030, necessitating an expansion of its manufacturing operations in the Dominican Republic[3] - The company is actively pursuing acquisition opportunities, having recently completed a small acquisition that enhances manufacturing capacity and talent[3] - The company has committed to a fifth building at its La Romana Robotic Surgery campus, with new equipment lines for two robotic surgery programs set to launch in the second half of the year[3] Assets - Total assets increased to $642.6 million as of March 31, 2025, compared to $629.0 million at the end of 2024[11] Sales Growth - Organic sales growth for Q1 2025 was 2.3%, despite a 15% decline in the Advanced Components business and a 6% decline in Robotic Surgery sales[3][4] Share Information - Weighted average diluted common shares outstanding slightly increased to 7,776 thousand in Q1 2025 from 7,737 thousand in Q1 2024[24]

UFP Technologies (UFPT) Q1 2025 Earnings Call May 06, 2025 10:00 AM ET Company Participants Ronald Lataille - SVP, Treasurer & CFOR. Jeffrey Bailly - Chairman & CEOJaeson Schmidt - Director of ResearchJustin Ages - Director - Equity ResearchAndrew Cooper - VP - Equity Research Conference Call Participants Brett Fishbin - Vice President & Senior Equity Research Analyst Operator Good day, and welcome to the UFP Technologies First Quarter of twenty twenty five Earnings Call. All participants will be in a liste ...

UFP Technologies (UFPT) Q1 2025 Earnings Call May 06, 2025 10:00 AM ET Speaker0 Good day, and welcome to the UFP Technologies First Quarter of twenty twenty five Earnings Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Also, please be aware that today's call is being recorded. I would now like to turn the call over to the Chief Financial Officer, Ron Lotae. Please go ahead, sir. Speaker1 Thank you, operator. Good morning and th ...

NEWBURYPORT, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ: UFPT), an innovative designer and custom manufacturer of components for medical devices, sterile packaging, and other highly engineered products, today announced the Company plans to report financial results for the first quarter ended March 31, 2025 on May 6, 2025 prior to market open. The Company will hold a conference call to discuss results the same day at 10:00 AM Eastern time. Conference Call Information:Date: Tuesd ...

Core Viewpoint - UFP Industries, Inc. reported disappointing first-quarter results for 2025, with both earnings and net sales falling short of expectations and declining year over year due to softer demand and pricing pressures [1][3]. Financial Performance - Earnings per share were $1.30, missing the Zacks Consensus Estimate of $1.59 by 18.2% and down 33.7% from the previous year [3]. - Net sales totaled $1.60 billion, below the consensus mark of $1.63 billion, representing a 2.7% year-over-year decline [3]. - The decline in sales was attributed to a 0.7% decrease in selling prices and a 2% drop in organic unit sales [3]. Segment Performance - **UFP Retail Solutions**: Reported net sales of $607 million, down 3% year over year, with organic unit sales decreasing by 4% [4]. Adjusted EBITDA margin contracted by 290 basis points to 5.9% [4]. - **UFP Packaging**: Net sales were $410 million, down 3% from the previous year, with a 1% decline in selling prices and a 3% drop in organic unit sales [5]. Adjusted EBITDA margin decreased by 190 basis points to 8.5% [5]. - **UFP Construction**: Net sales were $516 million, flat year over year, with organic unit sales growing by 3% but offset by a 3% decline in selling prices [6]. Adjusted EBITDA margin contracted by 320 basis points to 7.2% [7]. Operating Highlights - Selling, general and administrative expenses accounted for 11% of net sales, decreasing by 70 basis points year over year [8]. - Adjusted EBITDA was $142.2 million, down from $180.8 million year over year, with the adjusted EBITDA margin contracting by 210 basis points to 8.9% [8]. Balance Sheet & Cash Flow - As of March 29, 2025, the company had nearly $2.2 billion in liquidity, with cash and cash equivalents at $903.6 million, down from $1.17 billion at the end of 2024 [10]. - Long-term debt was $229.9 million, slightly up from $229.8 million at the end of 2024 [10]. - Net cash used in operating activities was $108.8 million, compared to $16.8 million in the same period last year [10]. Dividend and Share Repurchase - The board approved a quarterly dividend payment of 35 cents per share, a 6% increase from the previous dividend of 33 cents [11]. - The share repurchase program was amended to increase authorization from $200 million to $300 million, with $122 million remaining under the program as of April 28, 2025 [12]. Short-Term Outlook - The company anticipates subdued demand through the remainder of 2025, with a competitive pricing environment across all segments [14]. - UFPI is managing potential impacts from proposed tariffs on raw materials, believing it is well-positioned to adapt with minimal disruption [13]. Long-Term Outlook - Despite near-term challenges, UFPI aims for annual unit sales growth of 7-10% and targets EBITDA margins of 12.5% [15].